Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282183 | 0.94 | OPRK1 (0.55) | OPRK1TSHRPKMGAAHDAC6 | |
| SCHEMBL4281606 | 0.89 | PKM (0.54) | OPRK1PKMGAAHDAC6HDAC1 | |
| SCHEMBL4282270 | 0.88 | OPRK1 (0.49) | OPRK1TSHRPKMSMN1; SMN2GAA | |
| SCHEMBL4287162 | 0.86 | OPRK1 (0.66) | OPRK1TSHRPKMGAAHDAC6 | |
| SCHEMBL4291215 | 0.84 | OPRK1 (0.51) | OPRK1PKMGAAHDAC6HDAC1 | |
| SCHEMBL4291267 | 0.84 | OPRK1 (0.55) | OPRK1PKMGAAHDAC6HDAC1 | |
| SCHEMBL4289617 | 0.84 | OPRK1 (0.57) | OPRK1TSHRPKMGAAHDAC6 | |
| SCHEMBL4290251 | 0.84 | OPRK1 (0.51) | OPRK1PKMGAAHDAC6HDAC1 | |
| SCHEMBL4292503 | 0.83 | PKM (0.72) | OPRK1TSHRPKMSMN1; SMN2GAA | |
| SCHEMBL4288914 | 0.83 | HDAC6 (0.53) | OPRK1TSHRPKMSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | OPRK1 2640/4885TSHR 3226/4885PKM 847/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | OPRK1 2640/4885TSHR 3226/4885PKM 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.